Clover Biopharmaceuticals, Ltd.
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-…
Biotechnology
CN, Shanghai [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 44.34 | -0.64 | -1.14 | |
| Graham Fair Price | 0.00 | 2.05 | 2.05 | |
| PEG | inf | 0.00 | < 0.005 | |
| Price/Book | 25.50 | -0.91 | -1.22 | |
| Price/Cash Flow | 25.50 | -4.43 | -5.95 | |
| Prices/Earnings | 25.50 | -0.42 | -0.57 | |
| Price/Sales | -25.50 | 34.18 | 45.87 | |
| Price/FCF | 25.50 | -4.43 | -5.95 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | -11.19 | -11.19 | |
| Operating Margin | 0.00 | -21.77 | -21.77 | |
| ROA | 0.00 | -0.19 | -0.19 | |
| ROE | 0.54 | 0.54 | 0.00 | |
| ROIC | 1.02 | 1.07 | 4.65 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.06 | -0.31 | -80.90 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.52 | 0.00 | inf | |
| EPS QOQ | -2.23 | 0.00 | inf | |
| FCF QOQ | 0.31 | 0.00 | inf | |
| Revenue QOQ | 150.74 | 0.00 | inf | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 263.83 | 263.83 | 0.00 | |
| Days Sales Outstanding (DSO) | 111.26 | 111.26 | 0.00 | |
| Inventory Turnover | 0.34 | 0.34 | 0.00 | |
| Debt/Capitalization | -0.76 | -0.84 | -10.79 | |
| Quick Ratio | 0.34 | 0.35 | 3.60 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Bad
Fundamentals
Per Share Metrics
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | -0.59 | -0.59 | 0.00 | |
| Cash | 0.59 | 0.61 | 3.72 | |
| Capex | < 0.005 | < 0.005 | 0.00 | |
| Free Cash Flow | -0.12 | -0.12 | 0.00 | |
| Revenue | 0.02 | 0.02 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad